Secukinumab Treatment Protocol for Psoriasis
For adults with moderate-to-severe plaque psoriasis, initiate secukinumab at 300 mg subcutaneously at weeks 0,1,2,3, and 4, followed by 300 mg every 4 weeks as maintenance therapy. 1
Dosing Schedule
Standard Adult Regimen (Strength of Recommendation: A)
Loading Phase:
- 300 mg subcutaneous injection at weeks 0,1,2,3, and 4 1
Maintenance Phase:
- 300 mg every 4 weeks starting at week 8 1
Critical Dosing Note: The 300 mg dose is significantly more effective than 150 mg and should be the standard dose. While 150 mg may be acceptable for some patients, the higher dose achieves superior PASI 90 responses (79% vs 57.6% compared to ustekinumab at week 16) with equivalent safety 1. Do not use "as-needed" dosing after week 12—this approach is less effective than continuous every-4-week dosing 1.
Weight-Based Considerations
Body weight ≥90 kg with inadequate response at week 24:
- Consider intensifying to 300 mg every 2 weeks if PASI 90 not achieved 2
- Standard every-4-week dosing remains optimal for most patients, but heavier patients may benefit from dose intensification 2
Body weight-specific optimization:
- Patients 70-110 kg: maintain 300 mg every 4 weeks 3
- Patients ≥120 kg: consider 300 mg every 3 weeks 3
- Patients <70 kg: standard dosing remains appropriate 3
Pre-Treatment Screening
Infection Screening (Required)
Tuberculosis:
- PPD or interferon-gamma release assay
- Chest radiograph if indicated
- Do not initiate with active TB—treat latent TB before starting secukinumab 1
Hepatitis B:
- Screen for HBsAg and anti-HBc
- Relative contraindication if untreated hepatitis B infection 1
Active Infections:
- Absolute contraindication during active infection or sepsis
- Consult infectious disease specialist if considering initiation during active infection 1
- Temporarily discontinue for febrile illness requiring treatment; restart after full resolution and completion of antibiotics 1
Baseline Laboratory Assessment
- Complete blood count (CBC)
- Complete metabolic panel (CMP)
- Consider baseline inflammatory markers 1
Pregnancy and Contraception
Women of childbearing potential:
- Safety during pregnancy is uncertain—avoid use during pregnancy unless clearly necessary 1
- Discuss contraception and family planning before initiating therapy
Men attempting conception:
- Secukinumab is acceptable for men attempting conception with their partner 1
Lactation:
- Safety during lactation is uncertain 1
Management of Inadequate Response
Primary Failure (Week 12-24 Assessment)
If PASI 75 not achieved by week 12-16:
- Verify adherence to dosing schedule
- Consider body weight (if ≥90 kg, intensify to every 2 weeks) 2
- Optimize adjunctive topical therapy
- If no response by week 24, switch to alternative biologic 4
Secondary Failure (Loss of Response)
If initial response followed by loss of efficacy:
- Assess for:
- Medication adherence
- Weight gain (may require dose adjustment)
- Concurrent infections or inflammatory conditions
- Consider dose intensification if appropriate
- Switch to alternative biologic if optimization fails 4
Dose Escalation Strategy (if funded and feasible)
- From 300 mg every 4 weeks → 300 mg every 2 weeks
- This is off-label but may be considered for inadequate primary response, particularly in obese patients 4
- Associated with increased infection risk 4
Reinitiation After Treatment Interruption
If treatment interrupted:
- Repeat loading doses if:
- Patient is experiencing disease flare, AND/OR
- More than 3-4 half-lives have passed since previous dose (approximately 12-16 weeks) 1
- Otherwise, resume maintenance dosing schedule
Special Psoriasis Manifestations
Secukinumab is effective for:
- Nail psoriasis (Strength A) 1
- Palmoplantar plaque psoriasis (Strength A) 1
- Scalp psoriasis (Strength B) 1
- Palmoplantar pustulosis (Strength B) 1
- Erythrodermic psoriasis (Strength C) 1
- Psoriasis with psoriatic arthritis (Strength A) 1
Contraindications
Absolute Contraindications
- History of allergic reaction to secukinumab or vehicle 1
Relative Contraindications
- Untreated hepatitis B infection 1
- History of lymphoreticular malignancy 1
- Active infection or sepsis 1
- Inflammatory bowel disease (use with caution—may exacerbate Crohn's disease) 5
Safety Monitoring
Common Adverse Events
- Nasopharyngitis (most common)
- Candida infections (mild-to-moderate oral or genital candidiasis may occur) 5
- Reversible transient neutropenia 5
Ongoing Monitoring
- Monitor for signs of infection at each visit
- Temporarily discontinue for febrile illness requiring treatment 1
- Neutralizing antibodies are rare (<0.4%) and not associated with loss of efficacy 1
Vaccination Considerations
Non-live vaccines:
- Can be administered during treatment
- Antibody responses are preserved 6
Live vaccines:
- Avoid during treatment (standard precaution for immunosuppressive therapy)
Combination Therapy
Topical or systemic combinations:
- No published safety concerns with combination therapy
- Combination with topical or systemic therapies is considered safe 1
Pediatric Dosing (Age ≥6 years)
Weight-based dosing: